These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 26892115

  • 1. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
    Gülfe A, Wallman JK, Kristensen LE.
    Arthritis Res Ther; 2016 Feb 19; 18():51. PubMed ID: 26892115
    [Abstract] [Full Text] [Related]

  • 2. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group.
    JAMA Intern Med; 2017 Nov 01; 177(11):1605-1612. PubMed ID: 28975211
    [Abstract] [Full Text] [Related]

  • 3. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S, Everett CC, Naraghi K, Davies C, Dawkins B, Hulme C, McCabe C, Pavitt S, Emery P, Sharples L, Buch MH.
    Health Technol Assess; 2018 Jun 01; 22(34):1-280. PubMed ID: 29900829
    [Abstract] [Full Text] [Related]

  • 4. What PASSes for good? Experience-based Swedish and hypothetical British EuroQol 5-Dimensions preference sets yield markedly different point estimates and patient acceptable symptom state cut-off values in chronic arthritis patients on TNF blockade.
    Cooper A, Wallman JK, Gülfe A.
    Scand J Rheumatol; 2016 Nov 01; 45(6):470-473. PubMed ID: 27025702
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.
    Kvamme MK, Lie E, Uhlig T, Moger TA, Kvien TK, Kristiansen IS.
    Rheumatology (Oxford); 2015 Jul 01; 54(7):1226-35. PubMed ID: 25573840
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.
    Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, Hendriks L, Brouwer E, Visser H, Vonkeman HE, Hendrikx J, Jansen TL, Westhovens R, van de Laar MA, van Riel PL.
    Arthritis Res Ther; 2015 May 22; 17(1):134. PubMed ID: 25997746
    [Abstract] [Full Text] [Related]

  • 7. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
    Walker UA, Jaeger VK, Chatzidionysiou K, Hetland ML, Hauge EM, Pavelka K, Nordström DC, Canhão H, Tomšič M, van Vollenhoven R, Gabay C.
    Rheumatology (Oxford); 2016 Feb 22; 55(2):230-6. PubMed ID: 26316581
    [Abstract] [Full Text] [Related]

  • 8. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T, Baecklund E, Bengtsson K, Di Giuseppe D, Forsblad-d'Elia H, Askling J, ARTIS Study group.
    Ann Rheum Dis; 2018 May 22; 77(5):650-657. PubMed ID: 29237621
    [Abstract] [Full Text] [Related]

  • 9. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T, Philippe P, Drumez E, Deprez X, Cortet B, Duhamel A, Houvenagel E, Flipo RM.
    Int J Rheum Dis; 2016 Nov 22; 19(11):1093-1102. PubMed ID: 27018857
    [Abstract] [Full Text] [Related]

  • 10. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
    Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM.
    Arthritis Res Ther; 2016 Dec 01; 18(1):280. PubMed ID: 27906048
    [Abstract] [Full Text] [Related]

  • 11. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
    Xie F, Yun H, Bernatsky S, Curtis JR.
    Arthritis Rheumatol; 2016 Nov 01; 68(11):2612-2617. PubMed ID: 27213279
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH, Bae SC.
    Int J Rheum Dis; 2016 Nov 01; 19(11):1103-1111. PubMed ID: 26692536
    [Abstract] [Full Text] [Related]

  • 13. National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients.
    Karlsson JA, Nilsson JÅ, Neovius M, Kristensen LE, Gülfe A, Saxne T, Geborek P.
    Ann Rheum Dis; 2011 Dec 01; 70(12):2163-6. PubMed ID: 21859684
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M, Kaneko Y, Kondo H, Takeuchi T.
    Clin Rheumatol; 2016 Nov 01; 35(11):2829-2834. PubMed ID: 26971256
    [Abstract] [Full Text] [Related]

  • 15. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
    Jørgensen TS, Turesson C, Kapetanovic M, Englund M, Turkiewicz A, Christensen R, Bliddal H, Geborek P, Kristensen LE.
    PLoS One; 2017 Nov 01; 12(2):e0169946. PubMed ID: 28151971
    [Abstract] [Full Text] [Related]

  • 16. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden.
    Gülfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P.
    Ann Rheum Dis; 2010 Feb 01; 69(2):352-7. PubMed ID: 19282310
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
    Huoponen S, Aaltonen KJ, Viikinkoski J, Rutanen J, Relas H, Taimen K, Puolakka K, Nordström D, Blom M.
    PLoS One; 2019 Feb 01; 14(7):e0220142. PubMed ID: 31339961
    [Abstract] [Full Text] [Related]

  • 18. Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis.
    Md Yusof MY, Iqbal K, Darby M, Lettieri G, Vital EM, Beirne P, Dass S, Emery P, Kelly C.
    Rheumatology (Oxford); 2020 Oct 01; 59(10):2838-2846. PubMed ID: 32065634
    [Abstract] [Full Text] [Related]

  • 19. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis.
    Wunderlich C, Oliviera I, Figueiredo CP, Rech J, Schett G.
    Semin Arthritis Rheum; 2017 Jun 01; 46(6):709-714. PubMed ID: 28109618
    [Abstract] [Full Text] [Related]

  • 20. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
    Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL.
    Arthritis Res Ther; 2015 Nov 11; 17():319. PubMed ID: 26555431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.